Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : François ZhuWagih Ben HassenNicolas BricoutBasile KerlerouxKevin JanotBenjamin GoryRené AnxionnatSébastien RichardAdrien MarchalRaphael BlancMichel PiotinArturo ConsoliDenis TrystramChristine Rodriguez RegentJean-Philippe DesillesDavid Weisenburger-LileSimon EscalardDenis HerbreteauHeloise IferganIgor Lima MaldonadoJulien LabreucheHilde HenonOlivier NaggaraBertrand LapergueGrégoire Boulouis
• Organismes : Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Institut de psychiatrie et neurosciences de Paris Departement de Neuroradiologie [Lille] Institut de psychiatrie et neurosciences de Paris Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Régional Universitaire de Tours Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Imagerie Adaptative Diagnostique et Interventionnelle Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy] Défaillance Cardiovasculaire Aiguë et Chronique Service de neurologie [CHRU Nancy] Centre Hospitalier Régional Universitaire [CHU Lille] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Hôpital Foch [Suresnes] Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris Fondation Ophtalmologique Adolphe de Rothschild [Paris] Hôpital Foch [Suresnes] Fondation Ophtalmologique Adolphe de Rothschild [Paris] Centre Hospitalier Régional Universitaire de Tours Université de Tours Centre Hospitalier Régional Universitaire de Tours Imaging, Brain & Neuropsychiatry Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Département de neurologie [Lille] Institut de psychiatrie et neurosciences de Paris Hôpital Foch [Suresnes] Institut de psychiatrie et neurosciences de Paris Imaging, Brain & Neuropsychiatry
• Publié dans Stroke le 31/10/2020

---

Résumé : Background and Purpose: We aimed to evaluate among trained interventional neuroradiologist, whether increasing individual experience was associated with an improvement in mechanical thrombectomy (MT) procedural performance metrics. Methods: Individual MT procedural data from 5 centers of the Endovascular Treatment in Ischemic Stroke registry and 2 additional high-volume stroke centers were pooled. Operator experience was defined for each operator as a continuous variable, cumulating the number of MT procedures performed since January 2015, as MT became standard of care or, if later than this date, since the operator started performing mechanical thrombectomies in autonomy. We tested the associations between operator’s experience and procedural metrics. Results: A total of 4516 procedures were included, performed by 36 operators at 7 distinct centers, with a median of 97.5 endovascular treatment procedures per operator (interquartile range, 57–170.2) over the study period. Higher operator’s experience, analyzed as a continuous variable, was associated with a significantly shorter procedural duration (β estimate, −3.98 [95% CI, −5.1 to −2.8]; P<0.001), along with local anesthesia and M1 occlusion location in multivariable models. Increasing experience was associated with better Thrombolysis in Cerebral Infarction scores (estimate, 1.02 [1–1.04]; P=0.013). Conclusions: In trained interventional neuroradiologists, increasing experience in MT is associated with significantly shorter procedural duration and better reperfusion rates, with a theoretical ceiling effect observed after around 100 procedures. These results may inform future training and practice guidelines to set minimal experience standards before autonomization, and to set-up operators’ recertification processes tailored to individual case volume and prior experience.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Brigitte Tardy-PoncetEmmanuel de MaistreClaire PouplardEmilie PreslesMartine Alhenc-GelasDominique LasneMarie‐hélène HorellouChristine MoutonAnne Serre-SapinAnne BautersPhilippe NguyenFrançois MullierJulien PerrinGrégoire Le GalPierre‐emmanuel MorangeLélia GrunebaumAgnès Lillo-Le LouetIsmail ElalamyYves GruelAndreas GreinacherThomas LecompteBernard Tardy
• Organismes : Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne]
• Publié dans Journal of Thrombosis and Haemostasis le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Johanna AndersenSifat SharminMathilde LefortNils Koch-HenriksenFinn SellebjergPer Soelberg SørensenClaudia C. PflegerPeter RasmussenMichael JensenJette FrederiksenStephan BramowHenrik MathiesenKaren SchreiberDana HorakovaEva HavrdovaRaed AlroughaniGuillermo IzquierdoSara EichauSerkan OzakbasFrancesco PattiMarco OnofrjAlessandra LugaresiMurat TerziPierre GrammondFrancois Grand MaisonBassem YamoutAlexandre PratMarc GirardPierre DuquetteCavit BozMaria TrojanoPamela MccombeMark SleeJeannette Lechner-ScottRecai TurkogluPatrizia SolaDiana FerraroFranco GranellaVahid ShaygannejadJulie Prévost-ZuddasOlga SkibinaClaudio SolaroRana KarabudakBart WijmeerschTunde CsepanyDaniele SpitaleriSteve VucicRomain CaseyMarc DebouverieGilles EdanJonathan CironAurélie RuetJérôme SèzeElisabeth MaillartHélène ZéphirPierre M LabaugeGilles DeferChristine LebrunThibault MoreauEric BergerPierre ClavelouJean PelletierBruno StankoffOlivier GoutEric ThouvenotOlivier HeinzlefAbdullatif Al-KhedrBertrand BourreOlivier CasezPhilippe CabreAlexis MontcuquetAbir WahabJean-Philippe CamdessanchéAude MaroussetIvania PatryKarolina HankiewiczCorinne PottierNicolas MaubeugeCéline LabeyrieChantal NifleEmmanuelle LerayDavid-Axel LaplaudHelmut ButzkuevenTomas KalincikSandra VukusicMelinda Magyari
• Organismes : University of Copenhagen = Københavns Universitet University of Melbourne Recherche en Pharmaco-épidémiologie et Recours aux Soins École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Aarhus University Hospital Rigshospitalet [Copenhagen, Denmark] University of Copenhagen = Københavns Universitet Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire [Strasbourg] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Nice Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Régional Universitaire de Besançon CHU Clermont-Ferrand Hôpital de la Timone [CHU - APHM] Assistance publique - Hôpitaux de Paris (AP-HP) Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP] Centre Hospitalier Universitaire de Nîmes Institut de Génomique Fonctionnelle Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] CHU Amiens-Picardie CHU Rouen Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] CHU Limoges Hôpital Henri Mondor Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] CHU Trousseau [Tours] Centre Hospitalier de Saint-Denis [Ile-de-France] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier de Versailles André Mignot Centre d'Investigation Clinique [Rennes] Recherche en Pharmaco-épidémiologie et Recours aux Soins Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] École des Hautes Études en Santé Publique Département Méthodes quantitatives en santé publique Centre d’Investigation Clinique de Nantes Centre Hospitalier Universitaire de Nantes = Nantes University Hospital University of Melbourne University of Melbourne University of Copenhagen = Københavns Universitet University of Copenhagen = Københavns Universitet Copenhagen University Hospital [Denmark] = Københavns Universitetshospital [Danmark]
• Publié dans Multiple Sclerosis and Related Disorders le 24/10/2020

---

Résumé : Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening.Methods: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting.Results: The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod.Conclusion: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.

---

Fichiers liés : Andersen et al. - 2021 - The effectiveness of natalizumab vs fingolimod – a.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Sébastien ThureauNicolas PitonPierrick GouelRomain ModzelewskiAntoine DujonJean-Marc BasteJean MelkiPhilippe RinieriChristophe PeillonOlivier RastelliJustine LequesneSébastien HapdeyJean-Christophe SabourinPierre BohnPierre Vera
• Organismes : Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
• Publié dans Cancers le 21/10/2020

---

Résumé : Hypoxic areas are typically resistant to treatment. However, the fluorine-18-fluoroazomycin-arabinoside (FAZA) and fluorine 18 misonidazole (FMISO) tracers have never been compared in non small cell lung cancer (NSCLC). This study compares the capability of 18F-FAZA PET/CT with that of 18F-FMISO PET/CT for detecting hypoxic tumour regions in early and locally advanced NSCLC patients. We prospectively evaluated patients who underwent preoperative PET scans before surgery for localised NSCLC (i.e., fluorodeoxyglucose (FDG)-PET, FMISO-PET, and FAZA-PET). The PET data of the three tracers were compared with each other and then compared to immunohistochemical analysis (GLUT-1, CAIX, LDH-5, and HIF1-Alpha) after tumour resection. Overall, 19 patients with a mean age of 68.2 ± 8 years were included. There were 18 lesions with significant uptake (i.e., SUVmax >1.4) for the F-MISO and 17 for FAZA. The mean SUVmax was 3 (±1.4) with a mean volume of 25.8 cc (±25.8) for FMISO and 2.2 (±0.7) with a mean volume of 13.06 cc (±13.76) for FAZA. The SUVmax of F-MISO was greater than that of FAZA (p = 0.0003). The SUVmax of F-MISO shows a good correlation with that of FAZA at 0.86 (0.66–0.94). Immunohistochemical results are not correlated to hypoxia PET regardless of the staining. The two tracers show a good correlation with hypoxia, with FMISO being superior to FAZA. FMISO, therefore, remains the reference tracer for defining hypoxic volumes.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Maria Pia SormaniMarco SalvettiPierre M LabaugeIrene SchiavettiHélène ZéphirLuca CarmiscianoCaroline BensaNicola de RossiJean PelletierCinzia CordioliSandra VukusicLucia MoiolaPhilippe KerschenMarta RadaelliMarie ThéaudinPaolo ImmovilliOlivier CasezMarco CapobiancoJonathan CironMaria TrojanoBruno StankoffAlain CréangeGioacchino TedeschiPierre ClavelouGiancarlo ComiEric ThouvenotMario Alberto BattagliaThibault MoreauFrancesco PattiJérôme de SèzeCeline Louapre
• Organismes : Università degli studi di Genova = University of Genoa = Université de Gênes Università degli Studi di Roma "La Sapienza" = Sapienza University [Rome] Centre Hospitalier Régional Universitaire [Montpellier] Università degli studi di Genova = University of Genoa = Université de Gênes Lille Neurosciences & Cognition - U 1172 Università degli studi di Genova = University of Genoa = Université de Gênes Fondation Ophtalmologique Adolphe de Rothschild [Paris] Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia] Hôpital de la Timone [CHU - APHM] Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia] Hospices Civils de Lyon IRCCS Ospedale San Raffaele [Milan, Italy] Centre Hospitalier de Luxembourg [Luxembourg] Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy] Université de Lausanne = University of Lausanne Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Universitaire de Toulouse Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro Institut du Cerveau = Paris Brain Institute CHU Saint-Antoine [AP-HP] Service de neurologie [Mondor] Università degli studi della Campania "Luigi Vanvitelli" = University of the Study of Campania Luigi Vanvitelli CHU Clermont-Ferrand IRCCS Ospedale San Raffaele [Milan, Italy] Centre Hospitalier Universitaire de Nîmes Institut de Génomique Fonctionnelle Università degli Studi di Siena = University of Siena Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Università degli studi di Catania = University of Catania CIC Strasbourg Institut du Cerveau = Paris Brain Institute Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
• Publié dans Annals of Clinical and Translational Neurology le 04/03/2015

---

Résumé : We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.

---

Fichiers liés : acn3.51408.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Virginie CarmignacCyril MignotEmmanuelle BlanchardPaul KuentzMarie-Hélène Aubriot-LortonVictoria E.R. ParkerArthur SorlinSylvie FraitagJean-Benoît CourcetYannis DuffourdDiana RodriguezRachel G. KnoxSatyamaanasa PolubothuAnne BolandRobert OlasoMarc DelepineVéronique DarmencyMelissa RiachiChloé QuelinPaul RollierLouise GoujonSarah GrottoYline CapriMarie-Line JacquemontSylvie OdentDaniel AmramMartin ChevarinCatherine Vincent-DelormeBenoît CatteauLaurent GuibaudAlexis ArzimanoglouMalika KeddarCatherine SarretPatrick CallierDidier BessisDavid GenevièveJean‐françois DeleuzeChristel Thauvin-RobinetRobert SempleChristophe PhilippeJean-Baptiste RivièreVeronica KinslerLaurence FaivrePierre Vabres
• Organismes : Lipides - Nutrition - Cancer [Dijon - U1231] CHU Trousseau [APHP] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire de Tours Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand University of Cambridge [Cambridge, UK] Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Hôpital Necker - Enfants Malades [AP-HP] Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) CHU Pitié-Salpêtrière [AP-HP] University of Cambridge [Cambridge, UK] Great Ormond Street Hospital for Children [London] University College London [UCL] Institut de Génomique d'Evry Institut de Génomique d'Evry Institut de Génomique d'Evry Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand University College London [UCL] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] AP-HP Hôpital universitaire Robert-Debré [Paris] AP-HP Hôpital universitaire Robert-Debré [Paris] Centre Hospitalier Universitaire de La Réunion Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] CHI Créteil Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Hospices Civils de Lyon Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Institut Pascal CHU Clermont-Ferrand Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Régional Universitaire [Montpellier] Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB) Institut de Génomique d'Evry Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Hôpital d'Enfants [CHU Dijon] University of Cambridge [Cambridge, UK] The University of Edinburgh Lipides - Nutrition - Cancer [Dijon - U1231] Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Great Ormond Street Hospital for Children [London] University College London [UCL] Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon) Hôpital d'Enfants [CHU Dijon] Lipides - Nutrition - Cancer [Dijon - U1231] FHU TRANSLAD (CHU de Dijon)
• Publié dans Genetics in Medicine le 25/10/2020

---

Résumé : Purpose: Hypomelanosis of Ito (HI) is a skin marker of somatic mosaicism. Mosaic MTOR pathogenic variants have been reported in HI with brain overgrowth. We sought to delineate further the pigmentary skin phenotype and clinical spectrum of neurodevelopmental manifestations of MTOR-related HI. Methods: From two cohorts totaling 71 patients with pigmentary mosaicism, we identified 14 patients with Blaschko-linear and one with flag-like pigmentation abnormalities, psychomotor impairment or seizures, and a postzygotic MTOR variant in skin. Patient records, including brain magnetic resonance image (MRI) were reviewed. Immunostaining (n = 3) for melanocyte markers and ultrastructural studies (n = 2) were performed on skin biopsies. Results: MTOR variants were present in skin, but absent from blood in half of cases. In a patient (p.[Glu2419Lys] variant), phosphorylation of p70S6K was constitutively increased. In hypopigmented skin of two patients, we found a decrease in stage 4 melanosomes in melanocytes and keratinocytes. Most patients (80%) had macrocephaly or (hemi)megalencephaly on MRI. Conclusion: MTOR-related HI is a recognizable neurocutaneous phenotype of patterned dyspigmentation, epilepsy, intellectual deficiency, and brain overgrowth, and a distinct subtype of hypomelanosis related to somatic mosaicism. Hypopigmentation may be due to a defect in melanogenesis, through mTORC1 activation, similar to hypochromic patches in tuberous sclerosis complex.

---

Fichiers liés : 1-s2.0-S1098360021050668-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Claire Penetrat-RogerOlivier CollangeMyriam MezzarobbaOsama Abou-ArabLauranne TeuleMarc GarnierClément HoffmannLaurent MullerJean-Yves LefrantPierre-Grégoire GuinotEmmanuel NovyPaul AbrahamThomas ClavierJérémy BourenneGuillaume BeschLaurent FavierMichel FianiAlexandre OuattaraOlivier Joannes-BoyauMarc-Olivier FischerMarc LeoneYounes Ait TamlihatJulien PottecherPierre-Yves CordierPhilippe AussantMouhamed Djahoum MoussaEtienne HautinMarine BouexJean-Michel JuliaJulien CadyMarc Danguy Des DesertsNicolas MayeurThibault MuraBernard Allaouchiche
• Organismes : Centre Hospitalier Universitaire de Nîmes Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts Nouvel Hôpital Civil de Strasbourg Hôpitaux Universitaires de Strasbourg Centre Hospitalier Universitaire de Nîmes Université de Montpellier CHU Amiens-Picardie Centre Hospitalier Saint Jean de Perpignan Groupe de Recherche Clinique en Anesthésie Réanimation médecine PEriopératoire CHU Saint-Antoine [AP-HP] Hôpital d'instruction des Armées Percy Centre Hospitalier Universitaire de Nîmes Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts Centre Hospitalier Universitaire de Nîmes Initial MAnagement and prevention of acute orGan failures IN critically ill patiEnts Service d'anesthésie - réanimation chirurgicale [CHU de Dijon] Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy] Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Endothélium, valvulopathies et insuffisance cardiaque CHU Rouen Hôpital de la Timone [CHU - APHM] Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920) Centre Hospitalier Régional Universitaire de Besançon CH Béziers Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque - CHU de Bordeaux Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque - CHU de Bordeaux Service d'Anesthésie - Réanimation Chirurgicale [CHU Caen] Normandie Université Hôpital Nord [CHU - APHM] Aix Marseille Université Microbes Evolution Phylogénie et Infections Hôpitaux Universitaires de Strasbourg Mitochondrie, Stress oxydant et Protection musculaire Fédération de Médecine Translationnelle de Strasbourg Hôpital d'Instruction des Armées Laveran Centre hospitalier Robert Brisson [Lisieux] Centre Hospitalier Régional Universitaire [CHU Lille] Ramsay Santé Clinique de la Sauvegarde [Lyon] Centre Hospitalier Alès-Cévennes CRP Clinique du Parc, Castelnau-Le-Lez Institut Arnault Tzanck Hôpital d'Instruction des Armées Clermont Tonnerre Clinique Pasteur [Toulouse] Centre Hospitalier Universitaire de Nîmes Centre Hospitalier Lyon Sud [CHU - HCL]
• Publié dans Anaesthesia Critical Care & Pain Medicine le 27/10/2020

---

Résumé : Aim: Describing acute respiratory distress syndrome patterns, therapeutics management, and outcomes of ICU COVID-19 patients and indentifying risk factors of 28-day mortality.Methods: Prospective multicentre, cohort study conducted in 29 French ICUs. Baseline characteristics, comorbidities, adjunctive therapies, ventilatory support at ICU admission and survival data were collected.Results: From March to July 2020, 966 patients were enrolled with a median age of 66 (interquartile range 58-73) years and a median SAPS II of 37 (29-48). During the first 24 h of ICU admission, COVID-19 patients received one of the following respiratory supports: mechanical ventilation for 559 (58%), standard oxygen therapy for 228 (24%) and high-flow nasal cannula (HFNC) for 179 (19%) patients. Overall, 721 (75%) patients were mechanically ventilated during their ICU stay. Prone positioning and neuromuscular blocking agents were used in 494 (51%) and 460 (48%) patients, respectively. Bacterial co-infections and ventilator-associated pneumonia were diagnosed in 79 (3%) and 411 (43%) patients, respectively. The overall 28-day mortality was 18%. Age, pre-existing comorbidities, severity of respiratory failure and the absence of antiviral therapy on admission were identified as independent predictors of 28-day outcome.Conclusion: Severity of hypoxaemia on admission, older age (> 70 years), cardiovascular and renal comorbidities were associated with worse outcome in COVID-19 patients. Antiviral treatment on admission was identified as a protective factor for 28-day mortality. Ascertaining the outcomes of critically ill COVID-19 patients is crucial to optimise hospital and ICU resources and provide the appropriate intensity level of care.

---

Fichiers liés : S2352556821001351.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Brigitte Tardy-PoncetEmmanuel MaistreClaire PouplardEmilie PreslesMartine Alhenc‐gelasDominique LasneMarie‐hélène HorellouChristine MoutonAnne Serre‐sapinAnne BautersPhilippe NguyenFrançois MullierJulien PerrinGrégoire Le GalPierre MorangeLélia GrunebaumAgnès Lillo‐le LouetIsmail ElalamyYves GruelAndreas GreinacherThomas LecompteBernard Tardy
• Organismes : Santé Ingénierie Biologie Saint-Etienne Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Régional Universitaire de Tours Unité de Pharmacologie Clinique Santé Ingénierie Biologie Saint-Etienne Hôpital Européen Georges Pompidou [APHP] Hôpital Necker - Enfants Malades [AP-HP] CHU Tenon [AP-HP] Hôpital Européen Georges Pompidou [APHP] Laboratoire d'hématologie Centre Hospitalier Universitaire de Bordeaux CHU Clermont-Ferrand Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital universitaire Robert Debré [Reims] Université Catholique de Louvain = Catholic University of Louvain Centre Hospitalier Universitaire de Nancy Université d'Ottawa [Ontario] Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Centre Hospitalier Universitaire [Strasbourg] Hôpital Européen Georges Pompidou [APHP] Centre de Recherche Saint-Antoine CHU Trousseau [Tours] Greifswald University Hospital Geneva University Hospitals and Geneva University Santé Ingénierie Biologie Saint-Etienne
• Publié dans Journal of Thrombosis and Haemostasis le 27/10/2020

---

Résumé : Background Diagnosis of heparin-induced thrombocytopenia (HIT) requires pretest probability assessment and dedicated laboratory assays. Objective To develop a pretest score for HIT. Design Observational; analysis of prospectively collected data of hospitalized patients suspected with HIT (ClinicalTrials.gov NCT00748839). Setting Thirty-one tertiary hospitals in France, Switzerland, and Belgium. Patients Patients tested for HIT antibodies (2280 evaluable), randomly allocated to derivation and validation cohorts. Measurements Independent adjudicators diagnosed HIT based on the prospectively collected data and serotonin release assay results. Results Heparin-induced thrombocytopenia was diagnosed in 234 (14.7%) and 99 (14.5%) patients in the two cohorts. Eight features were associated with HIT (in brackets, points assigned for score calculation of the score): unfractionated heparin (1); therapeutic-dose heparin (1); cardiopulmonary bypass (cardiac surgery) (2); major trauma (3); 5- to 21-day interval from anticoagulation initiation to suspicion of HIT (4); >= 40% decrease in platelet count over <= 6 days (3); thrombotic event, arterial (3) or venous (3). The C-statistic was 0.79 (95% CI, 0.76-0.82). In the validation cohort, the area under the receiver operating characteristic curve was 0.77 (95% CI, 0.74-0.80). Three groups of scores were defined; HIT prevalence reached almost 30% in the high-probability group. Limitation The performance of the score may depend on settings and practices. Conclusion The objective, easy-to-collect, clinical features of HIT we evidenced were incorporated into a pretest score, which may guide clinical decisions regarding diagnostic testing and anticoagulation.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Alain CouretMelissa AllenMarcus Willi RackelBenjamin GalyJean- Philippe MonchouxVolker GütherFlorian PyczakPierre SallotMarc Thomas
• Organismes : Physique de la Plasticité et Métallurgie GfE Metalle and Materialien GmbH Helmholtz-Zentrum Geesthacht Centre d'élaboration de matériaux et d'études structurales Centre d'élaboration de matériaux et d'études structurales GfE Metalle and Materialien GmbH Helmholtz-Zentrum Geesthacht Safran Tech DMAS, ONERA, Université Paris Saclay [Châtillon]
• Publié dans Materialia le 23/10/2020

---

Résumé : During the last decade, it has been shown that the W-containing IRIS-TiAl alloy displays promising properties for structural applications at high temperatures. The manufacturing process of this alloy is divided into three successive steps: electrode production, powder atomisation and spark plasma sintering (SPS) densification. However, an IRIS alloy densified by using pre-alloyed powders atomized by EIGA process (Electrode Induction melting Gas Atomisation) has recently been found to exhibit chemical heterogeneities. The aim of the present work is to look for the origin of such heterogeneities all along this manufacturing process. The microstructures and the chemical compositions of the material obtained after these different steps are thus investigated at intermediate and local scales by using various experimental tools. A particular attention is paid to the distribution of tungsten atoms in correlation to the constituent phases. Effects of these heterogeneities on mechanical properties are measured by performing tensile tests at room and high temperatures. It will be demonstrated that these heterogeneities are issued from tungsten segregation occurring during the first stage of the initial solidification of the electrode, thus prior to atomisation.

---

Fichiers liés : CouretMateriala2021.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2021
• Auteurs : Jean‐philippe EmpanaPierre BoutouyrieCédric LemogneXavier JouvenThomas van Sloten
• Organismes : Paris-Centre de Recherche Cardiovasculaire
• Publié dans Biological Psychiatry le 01/11/2020

---

Fichiers liés : S0006322321012543.pdf

---

Source